The “low-risk” vendor that carries your highest exposure

by: Paul DavidsonPublished on: 31/03/2026

Most organisations classify certain vendors as “low risk” because they sit outside core trial activity or are unlikely to be inspected. Laboratories, PK providers, and early-stage research partners often fall into this category. But the data they generate still shapes key decisions about whether a compound progresses or stops, and may ultimately feed into clinical development. Having asked QA professionals for years about the risks in this space, there is one answer that is consistently overlooked. This article explores that gap, highlighting the sponsor’s ongoing responsibility for data integrity regardless of regulatory scope. It challenges the assumption that limited oversight is justified and examines the less visible risks, including missed opportunities where promising compounds are abandoned based on unreliable data. It also outlines how a more proportionate, risk-based approach to oversight can be applied in practice, helping organisations build confidence in the data that underpins some of their most important decisions.